Literature DB >> 21276427

Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.

Masashi Aoki1, Hitoshi Warita, Hideki Mizuno, Naoki Suzuki, Satoshi Yuki, Yasuto Itoyama.   

Abstract

We evaluated a battery of functional tests for investigating the effects of edaravone, a free radical scavenger, in SOD1 transgenic (H46R) rat model of amyotrophic lateral sclerosis. Edaravone (1.5 or 3.0mg/kg/h) or saline was administered intravenously to rats by continuous infusion (1h per day) for 2days, followed by a 2-day holiday. Lifetime and duration of illness were evaluated, and motor function was assessed using the hind-foot reflex test, landing foot-splay test, rota rod test and inclined plate test at a predetermined time point at which half of the control animals had died. Statistical comparison of motor functions of edaravone-treated and control SOD1 transgenic rats at an objectively determined time point was confirmed to be feasible. Edaravone-treated male rats showed significantly better performance in the landing foot-splay test. The present model seems suitable for evaluating motor function of H46R SOD1 transgenic rats, and be useful for examining the therapeutic potential of edaravone to treat amyotrophic lateral sclerosis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21276427     DOI: 10.1016/j.brainres.2011.01.058

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

2.  Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.

Authors:  Simon Witzel; André Maier; Robert Steinbach; Julian Grosskreutz; Jan C Koch; Anastasia Sarikidi; Susanne Petri; René Günther; Joachim Wolf; Andreas Hermann; Johannes Prudlo; Isabell Cordts; Paul Lingor; Wolfgang N Löscher; Zacharias Kohl; Tim Hagenacker; Christian Ruckes; Birgit Koch; Susanne Spittel; Kornelia Günther; Sebastian Michels; Johannes Dorst; Thomas Meyer; Albert C Ludolph
Journal:  JAMA Neurol       Date:  2022-02-01       Impact factor: 18.302

Review 3.  Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.

Authors:  Stephen A Johnson; Ton Fang; Fabiola De Marchi; Dylan Neel; Donatienne Van Weehaeghe; James D Berry; Sabrina Paganoni
Journal:  Drugs       Date:  2022-09-19       Impact factor: 11.431

4.  Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.

Authors:  Ken Ikeda; Yasuo Iwasaki
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 5.  Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions.

Authors:  Shyuan T Ngo; Jia D Mi; Robert D Henderson; Pamela A McCombe; Frederik J Steyn
Journal:  Degener Neurol Neuromuscul Dis       Date:  2017-07-25

Review 6.  Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives.

Authors:  Osama A Khairoalsindi; Ahmad R Abuzinadah
Journal:  Neurol Res Int       Date:  2018-08-12

7.  A circuit-dependent ROS feedback loop mediates glutamate excitotoxicity to sculpt the Drosophila motor system.

Authors:  Jhan-Jie Peng; Shih-Han Lin; Yu-Tzu Liu; Hsin-Chieh Lin; Tsai-Ning Li; Chi-Kuang Yao
Journal:  Elife       Date:  2019-07-18       Impact factor: 8.140

Review 8.  Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention.

Authors:  Teresa Cunha-Oliveira; Liliana Montezinho; Catarina Mendes; Omidreza Firuzi; Luciano Saso; Paulo J Oliveira; Filomena S G Silva
Journal:  Oxid Med Cell Longev       Date:  2020-11-15       Impact factor: 6.543

9.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

Authors:  Koji Abe; Yasuto Itoyama; Gen Sobue; Shoji Tsuji; Masashi Aoki; Manabu Doyu; Chikuma Hamada; Kazuoki Kondo; Takatomo Yoneoka; Makoto Akimoto; Hiide Yoshino
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-06       Impact factor: 4.092

Review 10.  How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Authors:  Kazutoshi Watanabe; Masahiko Tanaka; Satoshi Yuki; Manabu Hirai; Yorihiro Yamamoto
Journal:  J Clin Biochem Nutr       Date:  2017-11-11       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.